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Background: The VEGF pathway has become an important therapeutic target in lung cancer, where VEGF has long
been established as a potent pro-angiogenic growth factor expressed by many types of tumors. While Bevacizumab
(Avastin) has proven successful in increasing the objective tumor response rate and in prolonging progression and
overall survival in patients with NSCLC, the survival benefit is however relatively short and the majority of patients
eventually relapse. The current use of tyrosine kinase inhibitors alone and in combination with chemotherapy has
been underwhelming, highlighting an urgent need for new targeted therapies. In this study, we examined the
mechanisms of VEGF-mediated survival in NSCLC cells and the role of the Neuropilin receptors in this process.
Methods: NSCLC cells were screened for expression of VEGF and its receptors. The effects of recombinant VEGF
and its blockade on lung tumor cell proliferation and cell cycle were examined. Phosphorylation of Akt and Erk1/2
proteins was examined by high content analysis and confocal microscopy. The effects of silencing VEGF on cell
proliferation and survival signaling were also assessed. A Neuropilin-1 stable-transfected cell line was generated. Cell
growth characteristics in addition to pAkt and pErk1/2 signaling were studied in response to VEGF and its blockade.
Tumor growth studies were carried out in nude mice following subcutaneous injection of NP1 over-expressing cells.
Results: Inhibition of the VEGF pathway with anti-VEGF and anti-VEGFR-2 antibodies or siRNA to VEGF, NP1 and NP2
resulted in growth inhibition of NP1 positive tumor cell lines associated with down-regulation of PI3K and MAPK kinase
signaling. Stable transfection of NP1 negative cells with NP1 induced proliferation in vitro, which was further enhanced
by exogenous VEGF. In vivo, NP1 over-expressing cells significantly increased tumor growth in xenografts compared
to controls.
Conclusions: Our data demonstrate that VEGF is an autocrine growth factor in NSCLC signaling, at least in part,
through NP1. Targeting this VEGF receptor may offer potential as a novel therapeutic approach and also support the
evaluation of the role of NP1 as a biomarker predicting sensitivity or resistance to VEGF and VEGFR-targeted therapies
in the clinical arena.
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Despite improvements in conventional anti-cancer ther-
apies such as chemotherapy, radiotherapy and surgery,
the five-year survival for patients with non-small cell
lung cancer (NSCLC) remains poor. Vascular endothelial
growth factor (VEGF) is produced by most tumor types
and stimulates the growth of new blood vessels within a
tumor where it plays a pivotal role in the process of
angiogenesis [1]. The biological effects of VEGF are me-
diated via binding to specific tyrosine kinase receptors
including VEGFR-1 (Flt-1) and VEGFR-2 (KDR) in addi-
tion to non-tyrosine kinase receptors such as Neuropilin-1
(NP1) and Neuropilin-2 (NP2). Co-expression of NP1 and
NP2 in NSCLC tissue is significantly correlated with tumor
progression and poor prognosis [2]. NP1 has also been
shown to be an independent predictor of cancer relapse
and poor survival in NSCLC patients [3].
In Phase III trials, blocking VEGF using the recombin-
ant humanized VEGF monoclonal antibody Bevacizumab
(Avastin®) has proven successful in increasing the objective
tumor response rate and in prolonging progression-free
and overall survival in patients with NSCLC [4,5]. The
survival benefit is however relatively short and the major-
ity of patients eventually relapse. The current use of tyro-
sine kinase inhibitors alone and in combination with
chemotherapy has been underwhelming [6] and the pre-
cise effects of removing VEGF from the circulation
remains unclear. In a recent study [7], it was demon-
strated that circulating and tumor VEGF-A and NP1
tumor protein expression could select for patients most
likely to benefit from the addition of Bevacizumab to
chemotherapy in advanced or metastatic gastric cancer
patients. Patients with low baseline expression of NP1
showed a trend towards improved overall survival com-
pared to patients with high NP1 expression. These studies
suggest that NP1 may play an important role in VEGF-
mediated signaling in the tumor cells themselves.
In this study we demonstrate that VEGF is an auto-
crine growth and cell survival factor for NSCLC cells,
acting principally through the NP1 receptor, promoting
lung tumor growth. The results indicate that NP1, in
particular, should be evaluated as a predictive biomarker
with levels of expression potentially defining those pa-
tients most likely to benefit from VEGF targeted the-
rapies. Furthermore, NP1 may be a target for therapy in
NSCLC and other tumors.
Results
NSCLC cells express the classical VEGF and Neuropilin
receptors
A panel of NSCLC cell lines (H460, H647, A549 and
SKMES1) was screened for the expression of the VEGF
ligand (Figure 1A) and its receptors, VEGFR-1 (Flt-1),
VEGFR-2 (KDR), NP1 and NP2 at the mRNA (Figure 1B)and protein levels (Figure 1C). VEGF165 mRNA and pro-
tein was expressed in all cell lines examined. While low
levels of expression of VEGFR-1 and VEGFR-2 receptors
were found at the mRNA level, NP1 and NP2 mRNA ex-
pression was more abundant in all cell lines examined.
One may speculate that the low levels of VEGFR-1 and
VEGFR-2 mRNA detected may be due to the lower sen-
sitivity of RT-PCR over more sensitive and quantitative
methods such as real-time PCR. However, despite the
low levels of VEGFR-2 mRNA detected in these cells,
significantly higher levels of VEGFR-2 protein were de-
tected by western blot analysis. One possible explanation
for this observation is that the VEGFR-2 protein is an
inherently stable protein in these cells and does not
undergo extensive degradation and/or recycling within
the cell. As such, VEGFR-2 mRNA levels would be ex-
pected to be relatively low at steady-state levels and as
such, reflect this low-turnover of protein. While all cell
lines expressed VEGFR-2 at the protein level, VEGFR-1
protein was undetectable. NP1 protein expression was
observed in all cell lines except for the H460 cell line,
while NP2 protein was expressed in the adenocarcinoma
A549 and squamous SKMES1 cells only.
VEGF stimulates proliferation of Neuropilin-expressing
NSCLC cells
VEGF165 is a potent mitogen for endothelial cells, medi-
ating its biological effects via binding to its receptors
VEGFR-1, VEGFR-2 and the NPs. Therefore, the effect
of VEGF on the proliferation of NSCLC cells expressing
different profiles of these receptors was measured fol-
lowing the treatment of cells with recombinant human
VEGF (100 ng/ml) for 48 h (Figure 1D). VEGF stimu-
lated the proliferation of NSCLC cells expressing the
NP1 receptor (H647, A549 and SKMES1) with no effect
on the NP1-negative cell line, H460. These findings
demonstrate the role of VEGF165 in stimulating prolifer-
ation of NSCLC cells by interacting with the NP1 and/or
NP2 receptors in the presence of the cell signal transduc-
tion receptor, VEGFR-2 (KDR).
Neutralizing antibodies to VEGF inhibit proliferation of
lung tumor cells
The effect of neutralizing the biological activity of VEGF
on cell proliferation was examined in the VEGF respon-
sive cell lines A549 and SKMES1. Cells were treated
with increasing concentrations of VEGF neutralizing
antibodies (100 ng/ml-10 μg/ml) under reduced serum
(0.5%) conditions for 48 h, after which time cell prolifer-
ation was measured. An IgG isotype control antibody
was used to account for any non-specific effects of the
antibody on cell proliferation. Neutralizing VEGF resulted
in significant inhibition of cell proliferation in A549 and
SKMES1 cells at 10 μg/ml. In addition, proliferation of
Figure 1 (See legend on next page.)
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Figure 1 VEGF-mediated survival of NSCLC cells. Lung tumor cells were examined for their expression of VEGF mRNA and protein (A). The
VEGF receptors, VEGFR-1, VEGFR-2, NP1 and NP2 were also assessed at the mRNA (B) and protein (C) levels by RT-PCR and Western blot analysis,
respectively. All four NSCLC cell lines were treated with recombinant human VEGF (100 ng/ml) for 48 h. Cell proliferation was then measured
using the BrdU cell proliferation ELISA assay (*p < 0.05, VEGF vs untreated, n = 3) (D).
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also significantly decreased at 1 μg/ml (Figure 2A). We
further examined whether the addition of VEGF was able
to rescue cells following treatment with VEGF neutralizing
antibodies. Whilst VEGF partially rescued cells from the
effects of the monoclonal antibody, there was a statisti-
cally significant inhibition in proliferation of A549 and
SKMES1 cells (Figure 2B) when treated concurrently
with recombinant VEGF and neutralizing antibodies to
VEGF, relative to the proliferative effects of VEGF alone.
These results demonstrate that blocking VEGF inhibits
VEGF-mediated proliferation of NSCLC cells.
VEGF inhibition induces G0/G1 cell cycle arrest
In order to elucidate the mechanism underlying the
inhibitory effect of VEGF neutralizing antibodies on lung
tumor cell growth, changes in cell cycle distribution
were examined. Relative to untreated control cells (A549;
35%, SKMES1; 38%), a significant accumulation of cells in
the G0/G1 phase of the cell cycle was observed follow-
ing VEGF neutralization (A549; 60.38%, SKMES1; 53.66%)
(Figure 2C).
VEGF mediates cell survival signaling of lung cancer cells
via the PI3K and MAPK pathways
NSCLC cells were treated with VEGF to examine its
effect on the downstream signaling proteins of the
phosphatidylinositol-3-kinase (PI3K) and mitogen-activated
protein kinase (MAPK) signaling pathways using high
content analysis (HCA), confocal microscopy and western
blotting. Relative to untreated control cells, VEGF induced
significant phosphorylation of phospho-Akt and phospho-
MAPK (Erk1/2) in A549 (Figure 3A) and SKMES1 cells
(Additional file 1: Figure S2). The expression of both pro-
teins was observed mainly in the cytoplasmic com-
partment of both cell lines (Additional file 1: Figure S2).
VEGF antibody significantly decreased phospho-Akt to
below control levels. Similar results for phospho-Akt
expression in response to VEGF and its blockade were
also observed in SKMES1 cells. A significant increase in
phospho-MAPK expression (Erk1/2) was observed in
A549 and SKMES1 cells when treated with VEGF, while
inhibiting VEGF significantly decreased VEGF-induction
of pErk1/2. When cells were treated with both VEGF and
VEGF neutralizing antibodies, in combination, VEGF-
induced expression of pErk1/2 was significantly decreased.
Confocal imaging of pAkt (Figure 3B) and pErk1/2
(Additional file 1: Figure S3. ) signaling proteins in responseto VEGF and its blockade using neutralizing antibodies,
demonstrated similar findings to those found by high con-
tent screening analysis.
VEGF is an autocrine cell survival factor in non-small cell
lung cancer
To assess the importance of VEGF on lung cancer cell
survival, the effects of reducing VEGF expression in
A549 and SKMES1 cells were examined. A549 cells were
transfected with siRNA targeting the expression of
VEGF (siVEGF), reducing the steady-state levels of
VEGF mRNA by greater than 70%, as measured by
RT-PCR and confirmed by Western blot (Figure 3C).
A similar effect was also seen in SKMES1 lung cancer
cells (Additional file 1: Figure S4.). The effect of decreased
VEGF expression was examined on lung tumor cell
growth relative to untreated cells and cells treated
with scrambled controls. Significant inhibition of tumor
cell proliferation was observed in A549 (Figure 3D) and
SKMES1 (Additional file 1: Figure S4) cell lines. Phospho-
Akt expression was significantly decreased in response to
siVEGF in A549 and SKMES1 cells relative to untreated
and scrambled (siControl) controls (Figure 3E). A similar
effect was observed in the levels of expression of
phospho-MAPK (Erk1/2) in A549 cells, but to a lesser ex-
tent in SKMES1 cells, in which case, decreasing VEGF did
not significantly alter the MAPK pathway (Additional
file a1: Figure S4). Addition of recombinant VEGF to
siVEGF-treated cells significantly restored the expres-
sion of phospho-Akt to levels above that observed in
siVEGF-treated cells alone in both cell lines. Importantly,
the addition of VEGF to siVEGF-treated cells did not
affect phospho-Erk1/2 expression levels in A549 or
SKMES1 cells. These data further implicate the role
of PI3K and, to a lesser extent, MAPK pathways in
VEGF autocrine survival signaling in NSCLC.
Gene silencing of the Neuropilin receptors abrogates
tumor cell survival
To further extend our findings that NPs support VEGF
autocrine survival signaling in NSCLC, a siRNA strategy
was implemented to down-regulate the expression of
the VEGF receptors in A549 (Figure 4A) and SKMES1
(Figure 4B) cells. NP1 and NP2 siRNA abrogated protein
expression of both receptors at 24, 48 and 72 h post-
transfection. In order to examine whether VEGF supports
its autocrine function via VEGFR-2, cells were transfected
with siKDR similar to that for siNP1 and siNP2. Due to
Figure 2 VEGF blockade inhibits proliferation and induces cell cycle arrest of NSCLC cells. Cells were treated with neutralizing antibodies
to VEGF (100 ng/ml, 1 μg/ml, 10 μg/ml) for 48 h. An IgG isotype control was used as a control for antibody specificity. Cell proliferation was
measured using the BrdU assay (*p < 0.05, **p < 0.01, VEGF neutralizing antibody vs untreated, n = 3) (A). A549 and SKMES1 cells were treated
with either recombinant VEGF (rVEGF), neutralizing antibodies to VEGF (Anti-VEGF), or both combined (A549 cells, *p < 0.05, rVEGF + anti-VEGF;
*p < 0.01, untreated vs VEGF neutralizing antibody; **p < 0.001, untreated vs rVEGF, untreated vs rVEGF + Anti-VEGF, n = 3; SKMES1, *p < 0.05,
rVEGF + anti-VEGF, *p < 0.01, untreated vs rVEGF; *p < 0.001, untreated vs Anti-VEGF, untreated vs rVEGF + Anti-VEGF, n = 3) (B). To examine the
effect of VEGF on cell cycle distribution, NSCLC cells were treated with neutralizing antibodies to VEGF (10 μg/ml) for 48 h. Cell cycle analysis was
carried out (n = 2) by propidium idodide staining and examined by FACS (C). Where indicated, data are expressed as the mean ± SEM from three
independent experiments (n = 3). Statistical analysis was carried out by ANOVA using the Bonferroni multiple comparison post test.
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antibody approach was adopted to block VEGFR-2 (KDR).
In order to elucidate the effect of VEGF on A549 and
SKMES1 lung cancer cells upon knockdown/blockade ofall three VEGF receptors (NP1, NP2, KDR), a combined
siRNA (NP1, NP2) and receptor blockade (KDR) approach
was used (siCombo) in the presence or absence of VEGF.
In both A549 and SKMES1 cells, siNP1, siNP2 and KDR
Figure 3 (See legend on next page.)
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Figure 3 PI3K and MAPK signaling pathways are stimulated by VEGF. A549 cells were treated with recombinant human VEGF (100 ng/ml),
VEGF neutralizing antibodies (1 μg/ml) or both combined. Phospho-Akt and phospho-Erk1/2 expression (A) and localization (B) were examined
by high content screening (HCS) and confocal microscopy, respectively. Expression of the phosphorylated proteins, pAkt and pErk1/2, were
quantified using IN Cell Analyzer 1000 Software (phospho-Akt; *p < 0.05 untreated vs anti-VEGF, anti-VEGF vs combined, $p < 0.01 anti-VEGF vs
rVEGF; phospho-Erk1/2; $p < 0.01 untreated vs anti-VEGF, anti-VEGF vs combined, $#p < 0.001 untreated vs rVEGF, anti-VEGF vs rVEGF, anti-VEGF vs
combined, n = 3). Data are expressed as the mean ± SEM. Statistical analysis was carried out by ANOVA using the Bonferroni multiple comparison
post test. Localization and expression levels of phospho-Akt and p44/p42 MAPK (Erk1/2) proteins were examined (×60 magnification) using a Zeiss
LSM 510 laser scanning confocal microscope. Representative cells showing green fluorescence are indicative of phosphorylated Akt, while cell
nuclei are stained blue. PI3-K and MAPK signaling proteins were examined by Western blot in response to siVEGF (C). VEGF mRNA expression was
also assessed by RT-PCR to confirm knockdown of VEGF. A549 cells were treated with siRNA to VEGF (100nM) or a scrambled siRNA control for
48 h, after which time, cell proliferation was measured (D) (*p < 0.05, $p < 0.01, #p < 0.001, n = 3). Akt and MAPK (Erk1/2) phosphorylation was also
examined in response to siVEGF (E). Data are represented as the mean ± SEM. Statistical analysis was carried out by ANOVA using the Bonferroni
multiple comparison post test (#p < 0.05, *p < 0.01, $p < 0.001, n = 3).
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liferation relative to untreated and scrambled controls.
Knockdown/blockade of all three receptors signifi-
cantly inhibited cell survival of both A549 and SKMES1
cells to levels below that for each receptor alone. However,
when cells were treated with each siRNA and antibody in
combination, the differences observed in proliferation
were not statistically significant. Addition of recombinant
VEGF was unable to rescue cells from the growth inhi-
bitory effects of receptor blockade (Figure 4C), indicating
that these receptors are critical for VEGF-mediated
survival.
siNP1, siNP2 and KDR blockade significantly down-
regulated phospho-Akt expression in A549 and SKMES1
cells (Additional file 1: Figure S5). Only NP1 knockdown
significantly reduced pErk1/2 expression in A549 cells
with a trend towards a decrease in pErk1/2 seen following
treatment with siNP2 and anti-KDR. A non-significant de-
crease in pErk1/2 was evident following RNA inhib-
ition and anti-KDR monoclonal antibody therapy in
SKMES1 cells.
NP1 promotes survival and constitutive PI3-kinase signaling
of lung cancer cells and increases tumor growth in mice
The effect of NP1 over-expression on tumor cell prolif-
eration/survival was examined in H460 cells which nor-
mally do not express this receptor. H460 cells were
transiently transfected with a NP1 over-expression vec-
tor, pcDNA3.1(-)-NP1, and screened for its effects on
cellular proliferation and/or survival of H460 NSCLC
cells, compared to empty vector controls. Relative to
controls (set at 100%), a significant increase in tumor
cell growth was observed in H460 cells expressing the
NP1 pcDNA3.1 vector for 48 h (128 ± 4.8% vs control)
(Figure 5A). A stable transfectant was subsequently se-
lected using antibiotic selection with G418 (Geneticin)
at 800 μg/ml. Validation of NP1 over-expression was
carried out at the mRNA and protein levels in the
stably transfected cells (Figure 5B) and was found to
be over-expressed relative to control cells. Similar tothe effects observed for transient transfection, stable
over-expression of NP1 had a significant increase in
cellular proliferation at 72 h when compared to the empty
vector controls (172 ± 5.2% vs control) (Figure 5C). The
addition of exogenous VEGF had no effect on prolifera-
tion in cells transfected with the empty vector control,
pcDNA3.1(-). In contrast however, VEGF stimulation of
NP1 over-expressing cells induced a significant increase
in cell proliferation relative to empty vector controls
(224.5 ± 13.4% vs EVC control) and NP1 over-expressing
cells alone (224.5 ± 13.4% vs 172 ± 5.2%). Blocking VEGF
using neutralizing antibodies decreased proliferation of
NP1 over-expressing cells compared to untreated cells
(88.3 ± 1.2% vs untreated cells) (Figure 5D).
The effect of NP1 transfection on phosphorylation of
the downstream signaling intermediates, Akt and Erk1/2
proteins was also examined. Compared to empty vector
control cells, a significant increase in phosphorylated
Akt was found in NP1 over-expressing cells (159 ± 7.5%
vs EVC cells), but no change in levels of expression of
phosphorylated Erk1/2 proteins (110 ± 5.4% vs EVC cells)
(Figure 5E) was observed.
Based on these findings, and the effects of NP1 expres-
sion on lung tumor cell proliferation, an in vivo model was
used to examine the effect of NP1 receptor over-
expression on lung tumor growth. Following inoculation of
cells, tumor growth was monitored every 3-4 days for
24 days post-injection into the flanks of athymic nude
mice, and tumor volumes were recorded. A significant in-
crease in lung tumor growth was observed from as early as
day 10 compared to mice injected with control cells trans-
fected with empty control vector. At day 24, by which time
tumors had reached 2 cm3, lung tumor growth had in-
creased significantly (**p < 0.01) (Figure 5F) in mice injected
with NP1 over-expressing cells compared to the slower
growing tumors observed in the control group (Figure 5G).
Discussion
At present, drugs targeting angiogenic growth factors
are postulated as mediating their anti-tumor effects by
Figure 4 (See legend on next page.)
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Figure 4 Gene knockdown of VEGFR-2, NP1 and NP2 attenuates VEGF-mediated cell survival. VEGFR siRNA was carried out in A549
(A) and SKMES1 (B) lung cancer cells over 24, 48 and 72 h and protein expression was examined by Western blot analysis. NSCLC cells were
transfected with siNP1 (100 nM), siNP2 (100 nM), anti-KDR (10 μg/ml) antibody alone, and in combination, for 48 h. While an IgG isotype antibody
was used as a control for antibody specificity for KDR, proliferation in response to each siRNA was measured relative to a scrambled control siRNA
for siNP1 and siNP2. Exogenous recombinant VEGF (100 ng/ml) was added for a further 24 h following receptor knockdown/blockade, after which
time, cell proliferation was measured (C) (A549 cells, *p < 0.001, control vs siNP1, siNP2, siCombo, anti-KDR; #p < 0.05, control vs VEGF; $p < 0.05,
siNP1 + VEGF, siNP2 + VEGF, siCombo + VEGF, anti-KDR + VEGF vs VEGF alone, n = 3). (SKMES1 cells, *p < 0.001, control vs siNP1, siNP1, siCombo,
anti-KDR, VEGF alone; $p < 0.05, siNP1 + VEGF, siNP2 + VEGF, siCombo + VEGF vs VEGF alone; *p < 0.05, anti-KDR + VEGF vs VEGF alone, n = 3). Data
are expressed as the mean ± SEM from three independent experiments. Statistical analysis was carried out by ANOVA using the Bonferroni
multiple comparison post test.
Barr et al. Molecular Cancer  (2015) 14:45 Page 9 of 15inhibiting new blood vessel formation. Experimental
models have demonstrated that members of the VEGF
family promote tumor growth in vivo by inducing angio-
genesis [8]. When co-expressed in cells expressing
VEGFR-2, NP1 enhances the binding of VEGF165 to
VEGFR-2 and subsequent VEGF165-mediated chemo-
taxis [9,10]. Although the biological role of VEGFR-1
has remained unclear, cross-linking experiments have
shown that VEGF121 is able to bind both NP1 and NP2
in cells that co-express VEGFR-1, suggesting an inter-
action between VEGFR-1 and the NPs [11]. Although
experimental evidence indicates that endothelial migra-
tion and sprouting that is mediated by VEGF121 (which
binds to both NP1 and VEGFR-2, but cannot form
bridges between them) may be inhibited by anti-NP1
antibodies [12], it is possible that NP1 may have
functions that are independent of VEGFR-2, poten-
tially through the NP1 interacting protein (NIP) [13].
In xenograft experiments, anti-NP1 antibodies have a
modest suppressive effect on tumor growth, but signifi-
cant additive suppressive effects on tumor growth when
combined with anti-VEGF therapies [14]. This is accom-
panied by reductions in tumor vascular density and
maturity, suggesting that targeting NP1 is a valid anti-
angiogenic strategy and may help overcome resistance to
anti-VEGF therapies.
This anti-angiogenic hypothesis however fails to take
into consideration that in patients, tumor cells may pro-
liferate in the absence of neo-angiogenesis by co-opting
and modifying the existing vasculature. A role for VEGF
in preventing tumor cell apoptosis is supported by re-
ports demonstrating that over-expression of the soluble
VEGF receptor NP1, which prevents VEGF binding to
the cell surface receptors in tumor cells, is associated
with tumor cell apoptosis [15]. NP1 is expressed on
many tumor cell types and increased expression of
both NP1 and NP2 has been found to correlate with
tumor aggressiveness, advanced disease and poor progno-
sis [16,17].
To address the hypothesis that VEGF is a growth and
cell survival factor for NSCLC, cells were treated with
VEGF165 that binds to all four VEGF receptors, VEGFR-
1, VEGFR-2, NP1 and NP2. These data demonstratedthat VEGF stimulated growth of lung tumor cells
expressing NP1, but had no effect on cells that did not
express the NP1 receptor. Of interest was our finding
that H460 cells, in which NP1 receptor expression is
absent, failed to respond to VEGF despite its expression
of VEGFR-2. We believe that a critical element behind
VEGF-mediated cell survival involves the Neuropilin
receptors acting either as hetereodimers or homodimers.
It was previously hypothesized by Soker et al [10]
that in endothelial cells expressing both NP1 and VEGFR-2,
NP1 mediates VEGFR-2 activity by serving as a co-receptor,
thereby enhancing VEGF binding to the VEGFR-2 receptor
resulting in VEGF-mediated downstream signaling events,
chemotaxis and angiogenesis. As we currently know,
Neuropilins are unable to form homodimers, and as
such, must mediate their effects through heterodimeric in-
teractions with other receptors such as KDR or Plexins,
highlighting NP1, or NP2, as critical elements involved in
mediating VEGF signaling and supporting cell survival in
NSCLC.
In cells responding to recombinant VEGF protein,
neutralizing antibodies to VEGF inhibited lung tumor
cell growth and resulted in the arrest of cells in the G0/
G1 phase of the cell cycle, suggesting an important role
for VEGF signaling in lung tumor cells. Knockdown of
VEGF expression in cancer cells which are responsive to
VEGF, reduced cell proliferation further supporting a
role for VEGF as a cell growth and survival factor in
NSCLC. Such findings are in agreement with those previ-
ously reported [18] demonstrating a role for VEGF in the
survival of H1299 lung cancer cells expressing VEGFR-1,
VEGFR-2 and NP1. The effects of VEGF on downstream
proliferation and survival signaling in the NP1 expressing
cell lines, A549 and SKMES1, were clearly demonstrated
in this study with induction of phosphorylation of the
PI3K mediator Akt and, to a lesser extent, the MAPK sig-
naling proteins Erk1/2, respectively.
These results and other accumulating evidence suggest
that the function of VEGF in tumor progression may not
be limited to angiogenesis and that the more important
role of this pathway is in epithelial cell survival and pro-
liferation [19]. VEGF autocrine signaling via NP1 has
been demonstrated in breast cancer cells [20,21]. NP1
Figure 5 (See legend on next page.)
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Figure 5 H460 cells over-expressing NP1 promotes tumor growth in mice. H460 cells (NP1-negative) were transiently transfected with a NP1
over-expression vector, pcDNA3.1(-)-NP1, or empty vector control, pcDNA3.1(-) for 48 h and examined for its effect on cellular proliferation in the
presence or absence of VEGF (100 ng/ml) (A) (*p < 0.05 vs EVC). Validation of NP1 over-expression in stably transfected H460 cells was carried out
at the mRNA and protein levels using RT-PCR and Western blot analysis, respectively (B). The effect of VEGF stimulation on the proliferation of
empty vector control cells and NP1 stably transfected cells were examined using the BrdU Cell Proliferation ELISA (C) (*p < 0.05, **p < 0.01). The
response of NP1 over-expressing cells to VEGF blockade was examined using the BrdU Cell Proliferation ELISA following treatment with VEGF
neutralizing antibodies (D) (*p < 0.05). In order to further confirm a role of the PI3-K and MAPK signaling pathways in VEGF-mediated NP1 survival
signaling, protein expression of the downstream signaling proteins, phospho-Akt and phospho-Erk1/2, was examined by Western blot analysis (E)
(*p < 0.05). Using an in vivo model, a tumor growth study was carried out using NP1 over-expressing H460 lung tumor cells in female nude mice.
NP1 stably transfected H460 cells (3 × 106), or empty vector control cells, were injected subcutaneously on the left-hand side dorsal flank of each
mouse (n = 8/group). Tumor volumes were recorded every 3-4 days for 24 days (F). From day 7 and up to day 24, by which time tumors had
reached 2 cm3, lung tumor growth had increased significantly in mice injected with NP1 over-expressing cells (**p < 0.01; ***p < 0.001)
compared to the much slower growing tumors observed in the control (EVC) group (G). Data are represented as the mean ± SEM from three
independent experiments (A, C, D, and E). Statistical analysis for the in vitro analysis was carried out by ANOVA using the Bonferroni multiple
comparison post test. For the xenograft study, a non-parametric Mann-Whitney Test was used.
Barr et al. Molecular Cancer  (2015) 14:45 Page 11 of 15complexing with plexin-A1 involving both VEGF and
SEMA3a has been implicated in the chemotaxis of
breast cancer cell lines [22]. Preclinical data also support
a role for tumor cell NP1 in mediating lung and renal
cancer cell migration, proliferation and invasion [3,23].
In human FG pancreatic cells, over-expression of NP1
induced both Erk1/2 and JNK signaling pathways [24].
Down-regulation of the NP1 receptor using siRNA
sensitized PANC-1 cells to the cytotoxic effects of the
chemotherapeutic agent Gemcitabine, compared to NP1-
over-expressing cells. Such findings further implicate NP1
as a cell survival factor in epithelial tumors. In prostate
cancer, NP1 was found to be highly expressed by prostate
cancer cell lines and displayed a positive association with
invasiveness, suggesting that it may be one of the primary
receptors responsible for VEGF autocrine effects in pros-
tate cancer cells [25]. A positive association between NP1
expression and in vivo bone metastatic potential was
found in ARCaPM xenografts and was further confirmed in
clinical prostate cancer specimens. Hamerlik et al showed
that VEGF-VEGFR2-NP1-mediated signaling in glioma
stem-like cells is maintained in an autocrine manner
through the continuous secretion of VEGF, thereby allow-
ing constitutive activation of downstream pro-survival
pathways and growth of glioblastomas, tumor invasion
and increased resistance to treatment [26]. In other studies,
VEGF and NP1 expression by tumor epithelial cells also
regulates the stemness of cutaneous tumors and the expan-
sion of the cancer stem cell (CSC) pool, contributing to
enhanced tumor growth [27]. Conditional deletion of VEGF
in tumor epithelial cells caused tumors to regress, whereas
VEGF over-expression by tumor epithelial cells accelerated
tumor growth. In addition, VEGF affected skin tumor
growth by promoting cancer stemness and symmetric CSC
division leading to CSC expansion. When expressed as a
co-receptor in cutaneous CSCs, deletion of NP1 blocked
the ability of VEGF to promote cancer stemness and
renewal.Our data support the observations that NPs play a
central role in epithelial cancer cell survival. Stable
transfection of NP1 in NP1 non-expressing cells induced
NSCLC cell growth in vitro and in vivo. The in vitro
proliferation was augmented by addition of recombinant
VEGF. In contrast, stable knockdown of NP1, NP2 and
anti-VEGFR-2 antibody treatment induced inhibition of
tumor cell growth in NP1 positive lung adenocarcinoma
and squamous cell lines. This work cannot discount an
independent role for NP2 as a transmitter of cell survival
signaling for VEGF and this will be explored in future
studies. What is clear however, is that expression of NP1
together with VEGFR-2 may be critical for the autocrine
survival and growth effects of VEGF in NSCLC.
The combined targeting of ligand and co-receptor may
help to overcome resistance to targeted agents such as
bevacizumab in a subset of patients demonstrated to
over-express NP1. This is supported by preclinical data
demonstrating that anti-NP1 antibodies have additive
anti-cancer activity in combination with anti-VEGF
therapy [14]. A more comprehensive analysis of the
expression of NP1 by epithelial tumor cells may help
to inform prospectively planned biomarker driven
studies of the clinical benefit of bevacizumab, VEGFR-
and NP1-targeted agents. In this regard, recent studies
showing NP1 immuno-positivity by tumor cells in 6%
of primary and 14% of metastatic breast cancers, and
36% of primary and 50% of metastatic NSCLC pro-
vides a framework for testing this combined approach
in patients [28,29].
Conclusions
This study demonstrates that VEGF is an autocrine
growth factor for NP1 expressing NSCLC cells and may
have important implications for the pathogenesis and
treatment of NSCLC. These observations highlight the
critical role of VEGF and its cognate receptors, in par-
ticular the Neuropilins, in the survival of lung cancer
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of studies have reported expression of NP1 in a variety
of cancers such as prostate, pancreas, kidney, colorectal,
brain, breast and liver cancer. Therefore, targeting this
VEGF receptor may offer significant potential as a novel
therapeutic approach and may change the way clinicians
design studies aimed at targeting the VEGF survival
pathway in cancer patients. Our results also support the
evaluation of the role of NP1 as a biomarker predicting
sensitivity or resistance to VEGF and VEGFR-targeted
therapies in the clinical arena.
Methods
Cell lines
A panel of non-small cell lung cancer cells, H460 (large
cell carcinoma), H647 (adenosquamous carcinoma),
A549 (adenocarcinoma) and SKMES1 (squamous cell
carcinoma) were used. H460 and H647 cells were pur-
chased from the American Tissue Culture Collection
(ATCC), while A549 and SKMES1 cells were purchased
from the European Cell and Culture Collection (ECACC).
H460 and H647 cells were maintained in Roswell Park
Memorial Institute (RPMI-1640) medium in a humidified
atmosphere of 5% CO2 in air at 37°C. A549 cells were
maintained in Ham’s F12 supplemented with 4 mM L-glu-
tamine, while SKMES1 cells were cultured in EMEM
media supplemented with 2 mM L-glutamine and 1%
non-essential amino acids (NEAA). All media were sup-
plemented with 10% heat-inactivated fetal bovine serum
(FBS), penicillin (100 U/ml) and streptomycin (100 μg/ml)
(Lonza, UK). All cells were maintained as monolayer cul-
tures and exponentially growing cultures were used in all
experiments. All cell lines were tested and authenticated
six months prior to this study using the PowerPlex® 16 HS
System (Source BioScience, UK), a multiplex STR system.
Analysis of mRNA expression by RT-PCR
Total RNA was isolated using Tri-reagent (MRC Inc,
OH, USA). First-strand cDNA was prepared from 1 μg
of total RNA using Superscript III reverse transcriptase
(Invitrogen, UK) according to manufacturer’s instructions.
PCR reactions were carried out for the VEGF receptors,
VEGFR-1, VEGFR-2, NP1 and NP2. The endothelial cell
line, EAhy926, was used as a positive control. Primer
sequences used were as follows:
VEGFR-1 Forward: 5′CAAGTGGCCAGAGGCA
TGGAGTT3′
Reverse: 5′GATGTAGTCTTTACCATCCTGTTG3′
VEGFR-2 Forward: 5′GAGGGCCTCTCATGGTGA
TTGT3′
Reverse: 5′TGCCAGCAGTCCAGCATGGTCTG3′
NP1 Forward: 5′ATGGAGAGGGGGCTGCCG3′
Reverse: 5′CTATCGCGCTGTCGGTGTA3′NP2 Forward: 5′CCCCGAACCCAACCAGAAGA3′
Reverse: 5′GAATGCCATCCCAGATGTCCA3′
VEGF Forward: 5′CGCAAGCTTAGGAGTACCCT
GATGAG3′
Reverse: 5′CCGTCTAGAACATTTGTTGTGCTGT′
β-actin amplification was carried out in parallel to
account for loading differences between samples:
β-actin Forward: 5′TGTTTGAGACCTTCAACA
CCC3′
Reverse: 5′AGCACTGTGTTGGCGTACAG3′
Specificity of all primers was confirmed by comparing
the primer sequence for each gene against the Genbank
database. PCR products were analyzed on a 1% agarose
gel and images acquired using the BioSpectrum® Imaging
System (UVP, CA, USA).
Western blot analysis
Total protein was extracted from cells using ice-cold
RIPA buffer (50 mM Tris HCl, pH 7.4, 150 mM
NaCl, 1 mM EDTA, 1% (v/v) Triton-X 100, 0.1% (w/v)
SDS) supplemented with phenylmethylsulfonyl fluoride
(PMSF) and protease inhibitor cocktail (2 mM AEBSF,
1 mM EDTA, 130 μM Bestatin, 14 μM E-64, 1 μM
Leupeptin, 0.3 μM Aprotinin). Protein concentrations
were determined using the bicinchoninic acid assay
(BCA) as per manufacturer’s instructions. Protein
(40 μg) from whole cell lysates was fractionated on
8% or 12% SDS-PAGE gels and transferred to a PVDF
membrane (PALL Corporation, FL, USA). Transfer ef-
ficiency and loading was confirmed by reversible
staining of the membrane with Ponceau S solution
(Sigma-Aldrich, UK) following protein transfer. Mem-
branes were blocked at room temperature with 5%
non-fat dry milk in Tris-buffered saline (TBS) con-
taining 0.1% Tween-20 (TBS-T), followed by incuba-
tion with the appropriate primary antibodies at room
temperature or otherwise stated: rabbit anti-VEGF
(Millipore, CA, USA), 1:2000 at 4°C in 5% BSA TBS-T
(0.05%); mouse anti-Flt-1 (Millipore, CA, USA), 1:500 at
4°C in 3% Marvel TBS-T (0.05%); rabbit anti-KDR (Up-
state, USA), 1:5000 at room temperature in 5% Marvel
TBST-T (0.05%); goat anti-NP1 and rabbit anti-NP2
(Santa Cruz Biotech, CA, USA), 1:400 at room tempe-
rature in 5% Marvel TBS-T (0.1%); anti β-actin (Merck
Biosciences, UK), 1:20000 at room temperature in 5%
Marvel TBS-T (0.1%). Membranes were washed in TBST
and incubated with a secondary horseradish peroxid-
ase (HRP)-labeled antibody for 1 h at room temperature
(1:2000 at room temperature in 0.1% TBS-T). Membranes
were washed in TBST following incubation with second-
ary antibody. Bound antibody complexes were detected
and visualized using SuperSignal™ West Pico enhanced
chemiluminescence substrate (Pierce, IL, USA).
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Cell survival/proliferation was measured using the bro-
modeoxyuridine (BrdU) cell proliferation ELISA accord-
ing to manufacturer’s instructions (Roche Diagnostics,
Germany). BrdU labeling solution was added at a final
concentration of 10 μM. Cells were fixed for 60 min
followed by incubation for 90 min anti-BrdU antibody
(1:100). Wells were washed and incubated in substrate
solution. Absorbance was measured at 450 nm using a
reference wavelength at 690 nm.
High content imaging & confocal microscopy
NSCLC cells were seeded (1 × 104) in MatriPlate™ 96-well
glass bottomed micro-well plates (Matrical Bioscience,
WA, USA) and allowed to adhere overnight. Following
serum depletion (0.5% FBS), cells were treated with re-
combinant human VEGF (100 ng/ml), VEGF neutralizing
antibodies (1 μg/ml) or in combination, for 6 h. Cells were
fixed in 3% paraformaldehyde and washed in PBS. After
washing, cells were blocked in 5% normal goat serum for
1 h followed by incubation with primary rabbit phospho-
Akt (1:400) (Millipore) and phospho-p44/p42 MAPK
(1:400) (Cell Signaling Technology) primary antibodies in
4% BSA overnight at 4°C. Cells were washed in blocking
buffer and incubated with a secondary Alexa Fluor® 488
(Invitrogen) goat anti-rabbit antibody (1:1000), red phal-
loidin (1:1,000) and Hoechst 33342 (1:500) at room
temperature for 1 h. After washing in PBS, localization
and expression levels of phospho-Akt and phospho-Erk1/
2 were examined on the In Cell 1000 analyzer (GE Health-
care, UK) using IN Cell Investigator high-content image
analysis software (version 1.5). For confocal microscopy
analysis, NSCLC cells were seeded in glass chamber slides
and allowed to adhere overnight. Following serum deple-
tion (0.5% FBS), cells were treated with recombinant hu-
man VEGF (100 ng/ml) or VEGF neutralizing antibodies
(1 μg/ml) for 6 hrs. Cells were fixed in 3% paraformalde-
hyde and washed in PBS. After washing, cells were
incubated in blocking buffer containing 5% bovine
serum albumin (BSA) for 1 h and incubated with rabbit
phospho-Akt (1:200) and p44/p42 MAPK (Erk1/2) (1:50)
primary antibodies (Cell Signaling Technology) at 4°C
overnight. Cells were then washed in PBS and incubated
with a secondary Alexa Fluor® 488 (Invitrogen) goat anti-
rabbit antibody (1:1000) and Hoechst 33342 for nuclear
staining at room temperature for 1 h. After washing in
PBS, localization and expression levels of phospho-Akt
and phospho-Erk1/2 were examined using a Zeiss
LSM 510 laser scanning confocal microscope (Carl Zeiss
International, Germany).
Cell cycle analysis
Cells were detached and pelleted by centrifugation at
1300 rpm for 3 min. Supernatants were discarded andcells were suspended in 1 ml phosphate-buffered saline
(PBS) and fixed in 90% ice-cold ethanol. Following
incubation at room temperature for 30 min, cells
were resuspended in 1 ml PBS containing propidium
iodide (25 μg/ml) and DNase-free RNase A (100 μg/ml)
and left at 37°C for 30 min. DNA synthesis and cell
cycle distribution was measured by FACS (Becton
Dickinson, UK).
siRNA transient transfections
siRNA ON-TARGETplus SMART pool siRNA for NP1,
NP2, VEGF and VEGFR-2 (KDR) were designed and
synthesized (Dharmacon Inc, USA). Each siRNA pool
contains four individual sequences to silence target gene
expression at the mRNA level by at least 75%. A non-
targeting scrambled control was also included for each
target gene of interest. Cells at 60% confluence were
transfected in penicillin/streptomycin-free media with
each siRNA (100 nM) using DharmaFect1 transfection
reagent (Dharmacon Inc, USA) according to manufac-
turer’s instructions. After 6 h, siRNAs were removed and
cells were maintained in complete media for 24, 48 and
72 h. At each time point, total protein was extracted
from A549 and SKMES1 cells for Western blot analysis
to determine knockdown of each gene at the protein level.
As an alternative to siRNA, due to low levels of knock-
down of VEGFR-2, a blocking antibody to VEGFR-2
(sc-19530) (Santa Cruz Biotech, Germany) was also used.
Generation of NP1 stable transfected NSCLC cells
NP1 plasmid DNA was inserted into the site of the mam-
malian vector pcDNA3.1(-) (Invitrogen Corporation, CA,
USA) to generate pcDNA3.1(-)-NP1 plasmid constructs.
The NP1 plasmid constructs, including a pcDNA3.1(-)
empty vector control, were individually transfected into
the NP1 negative cell line, H460. Stable transfections were
carried out using FuGENE HD™ transfection reagent
(Roche Diagnostics Ltd., UK). Cells (3 × 105) were cultured
in their respective supplement-free medium and trans-
fected with either 1 μg pcDNA3.1(-)-NP1 or pcDNA-3.1
(-) (control vector) in antibiotic-free media containing
3 μL/mL FuGENE HD™ according to manufacturers’
instructions. Following transfection, cells were further in-
cubated for 24 h at 37°C. Antibiotic selection was then
carried out by treating the cells with Geneticin G418
(800 μg/mL). Following several rounds of antibiotic se-
lection, clones were selected and characterized at the
mRNA and protein levels in order to examine relative
NP1 expression levels.
In vivo tumor growth studies
Nude mice on a BALB/c background (CBy.CG-Foxn1nu)
were purchased from Jackson Laboratories (Bar Harbor,
MD, USA). Female mice, 10 weeks of age were utilized.
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ditions in individually ventilated and filtered cages under
positive pressure. All animal experiments were perfor-
med in compliance with Irish Department of Health and
Children regulations (Licence B100/3250) and approved
by the Trinity College Dublin BioResource Ethical Review
Board. Mice were anaesthetized with isofluorane and
injected subcutaneously on the left-hand side dorsal flank
with 3 × 106 H460 empty vector control cells (n = 8) or
3 × 106 NP1 stable transfectant cells (n = 8). Mice were
monitored and weighed weekly. Final tumor volume was
recorded using digital callipers and calculated based on
the equation (D1)2 × D2 × 0.524, where D1 is the smaller
of the two diameters of the tumor measured in both direc-
tions. Experiments were terminated when the tumor vol-
ume reached 2 cm3. Tumors were excised and retained
for further analyses. H460 cells (NP1-negative) were trans-
fected with a NP1 plasmid to over-express this receptor
for the in vivo component of this study.
Statistical analysis
Statistical analysis was carried out using analysis of vari-
ance (ANOVA) with post-hoc analysis using Bonferroni
multiple comparisons test, unless otherwise stated.
Where the means of two data sets were compared, an
unpaired Students t-test was used. Data is graphically
represented as mean ± standard error of the mean
(SEM) following three independent experiments, where
p < 0.05 was considered statistically significant. All data
were analyzed using GraphPad InStat™ (version 3.0)
statistical software.
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